Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG - PubMed (original) (raw)
Affiliations
- PMID: 15181132
Free article
Clinical Trial
Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG
Heikki Minn et al. J Nucl Med. 2004 Jun.
Free article
Abstract
Our aim was to evaluate the use of PET with (11)C-metomidate and (18)F-FDG for the diagnosis of adrenal incidentalomas.
Methods: Twenty-one patients underwent hormonal screening before dynamic imaging of the upper abdomen with (11)C-metomidate, and for 19 of these 21 patients, static (18)F-FDG imaging followed. Uptake of (11)C-metomidate and (18)F-FDG in incidentalomas was quantified and correlated with the hormonal work-up and the mass size on CT (median, 2.5 cm; range, 2-10 cm).
Results: The final diagnoses were hormonally active adenoma (n = 7), nonsecretory adenoma (n = 5), adrenocortical carcinoma (n = 1), pheochromocytoma (n = 2), benign noncortical tumor (n = 2), normal adrenal (n = 1), and malignant noncortical tumor (n = 3). Diagnosis was established at surgery (n = 9), percutaneous biopsy (n = 4), or follow-up (n = 8). The highest uptake of (11)C-metomidate, expressed as standardized uptake value (SUV), was found in adrenocortical carcinoma (SUV = 28.0), followed by active adenomas (median SUV = 12.7), nonsecretory adenomas (median SUV = 12.2), and noncortical tumors (median SUV = 5.7). Patients with adenomas had significantly higher tumor-to-normal-adrenal (11)C-metomidate SUV ratios than did patients with noncortical tumors. (18)F-FDG detected 2 of 3 noncortical malignancies but failed to detect adrenal metastases from renal cell carcinoma. All inactive and most active adenomas were difficult to detect with (18)F-FDG against background activity, whereas both pheochromocytomas and adrenocortical carcinoma showed slightly increased uptake of (18)F-FDG. There was no correlation between uptake of (11)C-metomidate or (18)F-FDG and mass size.
Conclusion: (11)C-Metomidate is a promising PET tracer to identify incidentalomas of adrenocortical origin. (18)F-FDG should be reserved for patients with a moderate to high likelihood of neoplastic disease.
Similar articles
- Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate.
Zettinig G, Mitterhauser M, Wadsak W, Becherer A, Pirich C, Vierhapper H, Niederle B, Dudczak R, Kletter K. Zettinig G, et al. Eur J Nucl Med Mol Imaging. 2004 Sep;31(9):1224-30. doi: 10.1007/s00259-004-1575-0. Epub 2004 Jun 10. Eur J Nucl Med Mol Imaging. 2004. PMID: 15197504 Clinical Trial. - PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate.
Bergström M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerström G, Långström B. Bergström M, et al. J Nucl Med. 2000 Feb;41(2):275-82. J Nucl Med. 2000. PMID: 10688111 - [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings.
Hennings J, Lindhe O, Bergström M, Långström B, Sundin A, Hellman P. Hennings J, et al. J Clin Endocrinol Metab. 2006 Apr;91(4):1410-4. doi: 10.1210/jc.2005-2273. Epub 2006 Jan 10. J Clin Endocrinol Metab. 2006. PMID: 16403816 - The role of PET in localization of neuroendocrine and adrenocortical tumors.
Eriksson B, Bergström M, Sundin A, Juhlin C, Orlefors H, Oberg K, Långström B. Eriksson B, et al. Ann N Y Acad Sci. 2002 Sep;970:159-69. doi: 10.1111/j.1749-6632.2002.tb04422.x. Ann N Y Acad Sci. 2002. PMID: 12381551 Review. - Metomidate-based imaging of adrenal masses.
Hahner S, Sundin A. Hahner S, et al. Horm Cancer. 2011 Dec;2(6):348-53. doi: 10.1007/s12672-011-0093-3. Horm Cancer. 2011. PMID: 22124841 Free PMC article. Review.
Cited by
- Functional imaging of neuroendocrine tumours with PET.
Mottaghy FM, Reske SN. Mottaghy FM, et al. Pituitary. 2006;9(3):237-42. doi: 10.1007/s11102-006-0269-y. Pituitary. 2006. PMID: 17036194 Review. - [18F]FDG-PET/CT in adrenal lesions: diagnostic performance in different clinical settings.
Romanisio M, Daffara T, Pitino R, Ferrero A, Pizzolitto F, Zavattaro M, Biello F, Gennari A, Volpe A, Sacchetti GM, Marzullo P, Aimaretti G, Prodam F, Caputo M. Romanisio M, et al. Endocrine. 2024 Sep 18. doi: 10.1007/s12020-024-04042-5. Online ahead of print. Endocrine. 2024. PMID: 39294519 - [18F]FETO: metabolic considerations.
Ettlinger DE, Wadsak W, Mien LK, Machek M, Wabnegger L, Rendl G, Karanikas G, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. Ettlinger DE, et al. Eur J Nucl Med Mol Imaging. 2006 Aug;33(8):928-31. doi: 10.1007/s00259-006-0123-5. Epub 2006 May 11. Eur J Nucl Med Mol Imaging. 2006. PMID: 16688452 - Contemporary imaging of incidentally discovered adrenal masses.
Gross MD, Korobkin M, Bou Assaly W, Dwamena B, Djekidel M. Gross MD, et al. Nat Rev Urol. 2009 Jul;6(7):363-73. doi: 10.1038/nrurol.2009.100. Epub 2009 Jun 9. Nat Rev Urol. 2009. PMID: 19506582 Review. - Masked volume wise Principal Component Analysis of small adrenocortical tumours in dynamic [11C]-metomidate Positron Emission Tomography.
Razifar P, Hennings J, Monazzam A, Hellman P, Långström B, Sundin A. Razifar P, et al. BMC Med Imaging. 2009 Apr 22;9:6. doi: 10.1186/1471-2342-9-6. BMC Med Imaging. 2009. PMID: 19386097 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical